| Old Articles: <Older 5771-5780 Newer> |
|---|
 |
The Motley Fool
July 20, 2009
Brian Orelli |
Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works.   |
The Motley Fool
July 17, 2009
Brian Orelli |
Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva. |
The Motley Fool
July 17, 2009
Brian Orelli |
Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson. |
The Motley Fool
July 17, 2009
Rick Aristotle Munarriz |
7 Reasons to Worry About Next Week Watch your step on the way down next week. Reports coming in from Apple... Coca Cola... Yahoo... Ebay... Amazon... Microsoft... Intuitive Surgical... |
The Motley Fool
July 16, 2009
Brian Orelli |
A Strong Dollar Can Hurt Novartis makes it through a hard quarter. |
The Motley Fool
July 16, 2009
Brian Orelli |
The Doctor Will Video Conference With You Now UnitedHealth Group and networking expert Cisco are setting up a telemedicine network that will include video conferencing and even a remote stethoscope. |
The Motley Fool
July 16, 2009
Brian Orelli |
Keep Your Chin Up, J&J An FDA advisory committee smacked down its drug candidate. |
The Motley Fool
July 15, 2009
Brian Orelli |
Less Inflammation From Abbott's Quarter Humira is headed back in the right direction. |
The Motley Fool
July 14, 2009
Brian Orelli |
J&J Eats a Hard Quarter Tough year-over-year comparisons are no match for the health care giant. |
The Motley Fool
July 14, 2009
Brian Orelli |
Diagnosing a Personalized Partnership Abbott and Glaxo hook up on diagnostics. |
| <Older 5771-5780 Newer> Return to current articles. |
